Abstract
We evaluated the GH-releasing effect of hexarelin (Hex; 2 μg/kg, iv) and GHRH (1 μg/kg, iv) in 18 patients (11 males and 7 females, aged 2.5- 20.4 yr) with GH deficiency (GHD) whose hypothalamic pituitary abnormalities had been previously characterized by dynamic magnetic resonance imaging (MRI). Ten patients had isolated GHD, and 8 had multiple pituitary hormone deficiency. All patients were receiving appropriate hormone replacement therapy. Twenty-four prepubertal short normal children (11 boys and 13 girls, aged 5.9-13 yr, body weight within ±10% of ideal weight) served as controls. MRI studies revealed an ectopic posterior pituitary at the infundibular recess in all patients. A residual vascular component of the pituitary stalk was visualized in 8 patients with isolated GHD (group 1), whereas MRI showed the absence of the pituitary stalk (vascular and neural components) in the remaining 10 patients (group 2), of whom 8 had multiple pituitary hormone deficiency and 2 had isolated GHD. In the short normal children, the mean peak GH response to GHRH (24.8 ± 4.4 μg/L) was significantly lower than that observed after Hex treatment (48.1 ± 4.9 μg/L; P <0.0001). In the GHD patients of group 2, the mean peak GH responses to GHRH (1.4 ± 0.3 μg/L) and Hex (0.9 ± 0.3 μg/L) were similar and markedly low. In the patients of group 1, the GH responses to GHRH (8.7 ± 1.3 μm/L) and Hex (7.0 ± 1.3 μg/L) were also similar, but were significantly higher that those observed in group 2 (P <0.0001). In the whole group of patients, a significant correlation was found between the GH peaks after Hex and those after GHRH (r = 0.746; P <0.0001). In this study we have confirmed that the integrity of the hypothalamic pituitary connections is essential for Hex to express its full GH-releasing activity and that Hex is able to stimulate GH secretion in patients with GHD but with a residual vascular component of the pituitary stalk.
| Original language | English |
|---|---|
| Pages (from-to) | 3886-3889 |
| Number of pages | 4 |
| Journal | Journal of Clinical Endocrinology and Metabolism |
| Volume | 83 |
| Issue number | 11 |
| Publication status | Published - 1998 |
Fingerprint
ASJC Scopus subject areas
- Biochemistry
- Endocrinology, Diabetes and Metabolism
Cite this
The growth hormone response to hexarelin in patients with different hypothalamic-pituitary abnormalities. / Maghnie, Mohamed; Spica-Russotto, Valeria; Cappa, Marco; Autelli, Michele; Tinelli, Carmine; Civolani, Patrizia; Deghenghi, Romano; Severi, Francesca; Loche, Sandro.
In: Journal of Clinical Endocrinology and Metabolism, Vol. 83, No. 11, 1998, p. 3886-3889.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The growth hormone response to hexarelin in patients with different hypothalamic-pituitary abnormalities
AU - Maghnie, Mohamed
AU - Spica-Russotto, Valeria
AU - Cappa, Marco
AU - Autelli, Michele
AU - Tinelli, Carmine
AU - Civolani, Patrizia
AU - Deghenghi, Romano
AU - Severi, Francesca
AU - Loche, Sandro
PY - 1998
Y1 - 1998
N2 - We evaluated the GH-releasing effect of hexarelin (Hex; 2 μg/kg, iv) and GHRH (1 μg/kg, iv) in 18 patients (11 males and 7 females, aged 2.5- 20.4 yr) with GH deficiency (GHD) whose hypothalamic pituitary abnormalities had been previously characterized by dynamic magnetic resonance imaging (MRI). Ten patients had isolated GHD, and 8 had multiple pituitary hormone deficiency. All patients were receiving appropriate hormone replacement therapy. Twenty-four prepubertal short normal children (11 boys and 13 girls, aged 5.9-13 yr, body weight within ±10% of ideal weight) served as controls. MRI studies revealed an ectopic posterior pituitary at the infundibular recess in all patients. A residual vascular component of the pituitary stalk was visualized in 8 patients with isolated GHD (group 1), whereas MRI showed the absence of the pituitary stalk (vascular and neural components) in the remaining 10 patients (group 2), of whom 8 had multiple pituitary hormone deficiency and 2 had isolated GHD. In the short normal children, the mean peak GH response to GHRH (24.8 ± 4.4 μg/L) was significantly lower than that observed after Hex treatment (48.1 ± 4.9 μg/L; P <0.0001). In the GHD patients of group 2, the mean peak GH responses to GHRH (1.4 ± 0.3 μg/L) and Hex (0.9 ± 0.3 μg/L) were similar and markedly low. In the patients of group 1, the GH responses to GHRH (8.7 ± 1.3 μm/L) and Hex (7.0 ± 1.3 μg/L) were also similar, but were significantly higher that those observed in group 2 (P <0.0001). In the whole group of patients, a significant correlation was found between the GH peaks after Hex and those after GHRH (r = 0.746; P <0.0001). In this study we have confirmed that the integrity of the hypothalamic pituitary connections is essential for Hex to express its full GH-releasing activity and that Hex is able to stimulate GH secretion in patients with GHD but with a residual vascular component of the pituitary stalk.
AB - We evaluated the GH-releasing effect of hexarelin (Hex; 2 μg/kg, iv) and GHRH (1 μg/kg, iv) in 18 patients (11 males and 7 females, aged 2.5- 20.4 yr) with GH deficiency (GHD) whose hypothalamic pituitary abnormalities had been previously characterized by dynamic magnetic resonance imaging (MRI). Ten patients had isolated GHD, and 8 had multiple pituitary hormone deficiency. All patients were receiving appropriate hormone replacement therapy. Twenty-four prepubertal short normal children (11 boys and 13 girls, aged 5.9-13 yr, body weight within ±10% of ideal weight) served as controls. MRI studies revealed an ectopic posterior pituitary at the infundibular recess in all patients. A residual vascular component of the pituitary stalk was visualized in 8 patients with isolated GHD (group 1), whereas MRI showed the absence of the pituitary stalk (vascular and neural components) in the remaining 10 patients (group 2), of whom 8 had multiple pituitary hormone deficiency and 2 had isolated GHD. In the short normal children, the mean peak GH response to GHRH (24.8 ± 4.4 μg/L) was significantly lower than that observed after Hex treatment (48.1 ± 4.9 μg/L; P <0.0001). In the GHD patients of group 2, the mean peak GH responses to GHRH (1.4 ± 0.3 μg/L) and Hex (0.9 ± 0.3 μg/L) were similar and markedly low. In the patients of group 1, the GH responses to GHRH (8.7 ± 1.3 μm/L) and Hex (7.0 ± 1.3 μg/L) were also similar, but were significantly higher that those observed in group 2 (P <0.0001). In the whole group of patients, a significant correlation was found between the GH peaks after Hex and those after GHRH (r = 0.746; P <0.0001). In this study we have confirmed that the integrity of the hypothalamic pituitary connections is essential for Hex to express its full GH-releasing activity and that Hex is able to stimulate GH secretion in patients with GHD but with a residual vascular component of the pituitary stalk.
UR - http://www.scopus.com/inward/record.url?scp=0031763970&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031763970&partnerID=8YFLogxK
M3 - Article
C2 - 9814463
AN - SCOPUS:0031763970
VL - 83
SP - 3886
EP - 3889
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
SN - 0021-972X
IS - 11
ER -